WO2019203338A1 - Composition contenant du turméronol a et/ou du turméronol b - Google Patents

Composition contenant du turméronol a et/ou du turméronol b Download PDF

Info

Publication number
WO2019203338A1
WO2019203338A1 PCT/JP2019/016764 JP2019016764W WO2019203338A1 WO 2019203338 A1 WO2019203338 A1 WO 2019203338A1 JP 2019016764 W JP2019016764 W JP 2019016764W WO 2019203338 A1 WO2019203338 A1 WO 2019203338A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
turmeronol
intake
tureronol
present
Prior art date
Application number
PCT/JP2019/016764
Other languages
English (en)
Japanese (ja)
Inventor
晋太郎 井出
正恵 上山
直弘 向田
健吾 川▲崎▼
隆正 内尾
知夏 花房
有沙 不破
Original Assignee
ハウスウェルネスフーズ株式会社
ハウス食品グループ本社株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハウスウェルネスフーズ株式会社, ハウス食品グループ本社株式会社 filed Critical ハウスウェルネスフーズ株式会社
Publication of WO2019203338A1 publication Critical patent/WO2019203338A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to compositions that are taken orally.
  • the invention also relates to an anti-inflammatory composition.
  • the present invention also relates to a composition for lowering blood CRP levels.
  • Prostaglandin E2 is produced by leukocytes (macrophages), mast cells, endothelial cells and platelets.
  • Arachidonic acid present as a component of cell membrane phospholipid is cleaved by phospholipase, and PGE2 is synthesized through a cyclooxygenase pathway. The pathway is activated in the process of inflammation, increasing the production of PGE2.
  • PGE2 released from specific cells acts on nearby target cells and induces an inflammatory reaction in the target cells.
  • PGE2 is one of chemical mediators for amplifying an inflammatory response at an inflammatory site, and activates the inflammatory response at the inflammatory site.
  • Nitric oxide is produced by type II nitric oxide synthase (iNOS) of leukocytes (macrophages) induced by inflammatory cytokines and bacterial endotoxins in the course of inflammation (Non-patent Document 1). Since excessively produced NO is converted to peroxynitrite and then shows cytotoxic effects such as DNA damage and LDL oxidation (Non-patent Document 2), excessive NO produced by inflammation can be suppressed. is important. In addition, since NO activates intracellular signal pathways that promote inflammation such as the NF- ⁇ B pathway (Non-patent Document 3), suppressing NO production is also important for exerting an anti-inflammatory effect ( Patent Document 1).
  • Inflammation is a protective reaction that is caused by stimulating factors such as infectious diseases, trauma, and foreign substances, and tries to eliminate self cells and tissues necrotized by the stimulating factor together with the stimulating factor itself.
  • the inflammatory response helps remove harmful stimuli, including infections.
  • inflammation can also damage normal tissues, it may cause damage to the living body, and it is necessary to suppress an excessive inflammatory reaction.
  • Patent Document 2 Examples of PGE2 production inhibitors and anti-inflammatory agents containing natural compounds as active ingredients include those described in Patent Document 2. Further, in Patent Document 1, a mixture of soybean seeds or an extract thereof and chlorophyll activated by light irradiation treatment and / or heat treatment has an activity of suppressing NO production and is useful as an anti-inflammatory agent. It is described that there is.
  • turmeric contains a large number of sesquiterpene compounds, and as a turmeric-derived sesquiterpene compound, a large number of bisaborane compounds such as tureronol A (Turmeronol A) and turmeronol B (Turmeronol B) are known.
  • a turmeric-derived sesquiterpene compound a large number of bisaborane compounds such as tureronol A (Turmeronol A) and turmeronol B (Turmeronol B) are known. (Non-Patent Document 4).
  • Patent Document 3 describes that turmeric rhizomes themselves, polysaccharides and essential oils in turmeric have anti-inflammatory effects.
  • Patent Document 3 further discloses that the active ingredient of turmeric can be divided into an essential oil fraction, a curcuminoid fraction, a turmerin fraction, and a polysaccharide fraction.
  • the essential oil fraction turmeronol A (turmeronol A) and turmeronol B are used together with turmer. It is described that (turmeronol B) is contained, and the essential oil fraction of turmeric rhizome can be extracted by a supercritical carbon dioxide extraction technique.
  • turmeric contains tureronol A and tureronol B as described in Non-Patent Document 4 and Patent Document 3, the effect of turmonol A and turmonol B itself was not clear.
  • Patent Document 3 quantification of turmeronol A and tureronol B in the turmeric extract is not performed.
  • An object of the present invention is to provide a composition having an anti-inflammatory action or a blood CRP value lowering action, which includes a compound derived from a food material rich in food experience and highly safe.
  • the present inventors have a composition containing at least one of turmeronol A and turmeronol B in a total amount of 100 ⁇ g or more, and a composition containing 80 ⁇ g or more of turmeronol A and / or 20 ⁇ g or more of turmeronol B per one intake.
  • the product has been found to have an anti-inflammatory action or a blood CRP value lowering action, and has led to the completion of the present invention described below.
  • compositions that is orally ingested and contains 80 ⁇ g or more of turmeronol A and / or 20 ⁇ g or more of turmeronol B per intake are derived from a turmeric extract.
  • An anti-inflammatory composition comprising at least one of tureronol A and turmeronol B in a total amount of 100 ⁇ g or more per one intake.
  • a composition for lowering CRP levels in blood comprising at least one of turmeronol A and turmeronol B in a total amount of 100 ⁇ g or more per one intake.
  • An anti-inflammatory composition comprising 80 ⁇ g or more of turmeronol A and / or 20 ⁇ g or more of turmeronol B per intake.
  • a composition for lowering the CRP level in blood comprising 80 ⁇ g or more of turmeronol A and / or 20 ⁇ g or more of turmeronol B per intake.
  • a composition comprising at least one of turmeronol A and turmeronol B in a total amount of 100 ⁇ g or more per intake for treating or preventing inflammation in a patient in need of treatment or prevention of inflammation.
  • (15) The use according to (9), the use according to (10), the method according to (11), or the composition according to (12), wherein the composition is taken orally.
  • a composition comprising 80 ⁇ g or more of turmeronol A and / or 20 ⁇ g or more of turmeronol B per dose for treating or preventing inflammation in a patient in need of treatment or prevention of inflammation.
  • the “patient” is a human or non-human animal, preferably a human.
  • composition comprising a compound derived from a food material rich in food experience and having a high safety, and having an anti-inflammatory action or a blood CRP value lowering action.
  • FIG. 1 shows the PGE2 concentration in the culture supernatant of RAW264.7 treated with turmeronol A.
  • FIG. 2 shows the concentration of PGE2 in the culture supernatant of RAW 264.7 treated with tureronol B.
  • FIG. 3 shows the NO 2 ⁇ concentration in the culture supernatant of RAW 264.7 treated with tureronol A.
  • FIG. 4 shows the NO 2 ⁇ concentration in the culture supernatant of RAW 264.7 treated with tureronol B.
  • FIG. 1 shows the PGE2 concentration in the culture supernatant of RAW264.7 treated with turmeronol A.
  • FIG. 2 shows the concentration of PGE2 in the culture supernatant of RAW 264.7 treated with tureronol B.
  • FIG. 3 shows the NO 2 ⁇ concentration in the culture supernatant of RAW 264.7 treated with tureronol A.
  • FIG. 4 shows the NO 2 ⁇ concentration in the culture supernatant of
  • Tameronol A and Tameronol B are compounds having the following planar structures, respectively.
  • tureronol A and turmeronol B are known to have S-configuration at the 6-position carbon in the partial structure of 2-methyl-2-hepten-4-one. is there.
  • tereronol A and tereronol B only have to have the above-described planar structure, and the configuration may be S-form, R-form, S-form and R-form. And a mixture thereof.
  • turmonol A and / or turmonol B is preferably turmonol A and / or turmonol B derived from a turmeric extract.
  • turmonol A and / or turmonol B derived from the turmeric extract may be turmonol A and / or turmonol B separated from the turmeric extract, or turmonol A existing as a component in the turmeric extract.
  • / or tureronol B is preferably turmonol A and / or turmonol B derived from a turmeric extract.
  • turmonol A and / or turmonol B derived from the turmeric extract may be turmonol A and / or turmonol B separated from the turmeric extract, or turmonol A existing as a component in the turmeric extract.
  • / or tureronol B may be turmonol A and / or turmonol B separated from the turmeric extract.
  • the turmeric extract refers to an extract (turmeric extract) of a plant raw material derived from a plant belonging to the genus Turmeric belonging to the ginger family.
  • the turmeric extract is not limited to the solvent extract obtained by extraction with an extraction solvent, but also includes those obtained by further fractionating and purifying the solvent extract by column chromatography or the like.
  • the turmeric extract used in the present invention is obtained from an extract obtained by completing the extraction operation (including fraction purification in the case of fraction purification), a concentrate obtained by partially removing the solvent from the extract, or an extract. It can be in the form of a dry product from which the solvent has been removed.
  • the removal of the solvent from the extract can be performed by volatilizing the solvent by heating and / or reduced pressure. These heating and decompression methods are not particularly limited, and for example, conventionally known methods can be used.
  • plant raw materials examples include Curcuma longa (turmeric), Curcuma aromatica, Curcuma zedoaria, Curcuma phaeocaulis, Curcuma kwangsiens, Curcuminc, and Curcumacurium.
  • a Curcuma longa rhizome is preferred. As the rhizome, one collected from soil may be used, and an appropriate portion of the rhizome may be used as it is, cut into an appropriate size or shape, or pulverized. These plant materials may be appropriately dried.
  • the extraction solvent include at least one selected from the group consisting of water and a hydrophilic organic solvent, a liquid solvent such as hexane, water vapor, and a supercritical fluid.
  • the at least one extraction solvent selected from the group consisting of water and a hydrophilic organic solvent may be any of water, a hydrophilic organic solvent, and a mixed solvent of water and a hydrophilic organic solvent.
  • the hydrophilic organic solvent may be a mixed solvent of plural kinds of hydrophilic organic solvents.
  • Water includes hot water. As hot water, for example, hot water of 95 ° C. or higher can be used.
  • the hydrophilic organic solvent include at least one alcohol (may be a mixed solvent of a plurality of alcohols), and the alcohol is not particularly limited, but ethanol is preferable.
  • the mixing ratio in the case of using a mixed solvent of alcohol and water as the extraction solvent is not particularly limited. For example, the weight ratio is preferably in the range of 10:90 to 90:10, and more preferably in the range of 20:80 to 50:50. .
  • Extraction using steam is also called steam distillation.
  • Supercritical carbon dioxide is preferred as the supercritical fluid.
  • ethanol, hexane or supercritical fluid is preferable to use ethanol, hexane or supercritical fluid as the extraction solvent.
  • Curcumin contained in turmeric is a kind of curcuminoid.
  • the international organization JECFA FAO / WHO Joint Expert Committee on Food Additives
  • ADI permisible daily intake
  • curcuminoids 3 mg / kg body weight / day (eg, 150 mg per day for a person with a body weight of 50 kg). Therefore, when using turmeronol A and / or turmonol B in the form of a turmeric extract, it is preferable to use a turmeric extract containing turmonol A and / or turmonol B and having a low curcuminoid concentration.
  • water particularly hot water
  • hexane water vapor or a supercritical fluid
  • the method for preparing the turmeric extract using the extraction solvent is not particularly limited.
  • Turmonol A and / or turmonol B may be used in the form of a plant material containing it.
  • the plant raw material containing turmonol A and / or turmonol B include the raw materials of the ginger family turmeric genus described above.
  • the rhizome of the ginger family turmeric genus plant contains both iron and turmeronol A and / or turmonol B relatively. Ingestion of large amounts of iron may adversely affect people with specific symptoms such as hepatitis C patients and NASH (non-alcoholic steatohepatitis), so the recommended upper limit of iron intake is 1 6 mg per day. For this reason, it is preferable that turmeronol A and / or turmeronol B are forms other than the rhizome form of the ginger family turmeric genus plant.
  • the composition of the present invention contains at least one of turmeronol A and turmeronol B in a total amount of 100 ⁇ g or more per one intake.
  • the content of one of them may be 100 ⁇ g or more per one intake.
  • the total content of both is included, it may be 100 ⁇ g or more per one intake.
  • the composition according to the first aspect has an action of suppressing inflammation, particularly chronic inflammation, and an action of reducing CRP (c-reactive protein) level in blood when ingested by animals such as humans. Played.
  • the composition according to the first aspect comprises a total of 100 ⁇ g or more of turmeronol A and turmeronol B per intake, and more preferably 80 ⁇ g or more of turmeronol per intake.
  • the composition of the present invention contains 80 ⁇ g or more of turmeronol A and / or 20 ⁇ g or more of turmeronol B per one intake.
  • the composition according to the second aspect has an action of suppressing inflammation, particularly chronic inflammation, and an action of reducing the CRP (c-reactive protein) level in blood when ingested by animals such as humans. Played.
  • the composition according to the second aspect contains 80 ⁇ g or more of turmeronol A and 20 ⁇ g or more of turmeronol B per serving.
  • the method for quantifying tureronol A and tureronol B is not particularly limited, and can be performed, for example, by LC / MS analysis shown in Examples.
  • the tereronol A and / or the turmeronol B is added to the tereronol A and / or tereronol B at the time of completion of production, that is, at the stage of shipment of the production factory as a finished product. It only has to be included in the range.
  • the composition according to the first aspect or the second aspect of the present invention has a curcumin content per intake of less than 30 mg.
  • Compositions with a curcumin content of less than 30 mg per dose will reduce inflammation and blood CRP without exceeding the curcuminoid ADI (permissible daily intake) (150 mg for a 50 kg person). Since it is easy to ingest an amount of turmeronol A and / or turmeronol B effective for lowering the value, it is preferable.
  • a single intake means an amount at which the composition of the present invention is ingested at a time, or continuously over a short time interval (for example, 10 minutes or less, preferably 5 minutes or less). This means the total amount taken multiple times.
  • composition of the present invention is in the form of a liquid or fluid composition
  • 0.1 ml to 500 ml typically 50 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml or 500 ml
  • 0.1 g to 500 g typically 50 g, 100 g, 150 g, 200 g, 250 g, 300g, 350g, 400g, 450g or 500g
  • “one intake” is used in this sense.
  • compositions taken orally In a preferred embodiment, the composition according to the first aspect or the second aspect of the present invention is a composition to be taken orally.
  • composition that is orally ingested according to the present invention exhibits preferable effects such as suppression of inflammation and reduction of blood CRP value when animals such as humans are orally ingested.
  • composition to be orally ingested according to the present invention may be a composition in various forms such as pharmaceuticals, foods and drinks, feeds, food additives, feed additives, etc. It is more preferable.
  • the foods and drinks include foods in the form of functional display foods, foods for specified health use, supplements for nutritional supplements, and the like.
  • the orally ingested composition of the present invention may be continuously ingested, or may be ingested when necessary.
  • composition according to the first aspect or the second aspect of the present invention is an anti-inflammatory composition.
  • the anti-inflammatory composition of the present invention is useful for the prevention or treatment of inflammation, particularly chronic inflammation, in animals such as humans.
  • Still another embodiment of the present invention is the use of the composition according to the first aspect or the second aspect of the present invention for the manufacture of an anti-inflammatory composition.
  • Still another embodiment of the present invention is the use of the composition according to the first aspect or the second aspect of the present invention for the manufacture of an anti-inflammatory drug.
  • Yet another embodiment of the present invention provides: Administering the composition according to the first aspect or the second aspect of the present invention to a patient in need of treatment or prevention of inflammation, and treating or preventing inflammation in the patient, A method of treating or preventing inflammation.
  • composition according to the first aspect or the second aspect of the present invention for treating or preventing inflammation in a patient in need of treatment or prevention of inflammation.
  • the anti-inflammatory composition, or the composition or pharmaceutical used for the treatment or prevention of inflammation is a composition in various forms such as pharmaceuticals, foods and drinks, feeds, food additives, feed additives and the like. It may be a medicine or a food or drink taken by a human.
  • the foods and drinks include foods in the form of functional display foods, foods for specified health use, supplements for nutritional supplements, and the like.
  • the anti-inflammatory composition or the composition or medicament used for the treatment or prevention of inflammation is preferably in the form of a composition taken orally or nasally, more preferably taken orally. In the form of a composition.
  • the anti-inflammatory composition, or the composition or medicament used for the treatment or prevention of inflammation may be ingested continuously or may be ingested when necessary. Good.
  • the anti-inflammatory composition or the specific form of the composition or medicament used for the treatment or prevention of inflammation will be described later.
  • composition according to the first aspect or the second aspect of the present invention is a composition for lowering the blood CRP value.
  • composition for lowering the blood CRP level of the present invention has the effect of lowering the blood CRP (c-reactive protein) level, which is an indicator of inflammation, particularly chronic inflammation, in animals such as humans.
  • CRP c-reactive protein
  • the blood CRP value is also an index of risk other than inflammation, for example, risk of cardiovascular disease such as arteriosclerosis.
  • CRP is known to be related to exacerbation of arteriosclerosis, and blood CRP measurement is used for predicting the risk of cardiovascular disease.
  • the composition having a blood CRP level lowering action can be used not only for the treatment or prevention of inflammation but also for the treatment or prevention of cardiovascular disease.
  • Still another embodiment of the present invention is the use of the composition according to the first aspect or the second aspect of the present invention for the production of a composition for lowering blood CRP levels.
  • Still another embodiment of the present invention is the use of the composition according to the first aspect or the second aspect of the present invention for the manufacture of a medicament for lowering the blood CRP value.
  • Yet another embodiment of the present invention provides: Administering the composition according to the first aspect or the second aspect of the present invention to a patient in need of lowering the blood CRP value, and lowering the blood CRP value in the patient; And a method for lowering the CRP level in blood.
  • composition according to the first aspect or the second aspect of the present invention for lowering blood CRP level in a patient in need of lowering blood CRP level.
  • the composition for lowering the blood CRP value, or the composition or medicine used for lowering the blood CRP value includes compositions of various forms such as pharmaceuticals, foods and drinks, feeds, food additives, feed additives, etc. It may be a thing, and it is more preferable that it is a pharmaceutical or food or drink taken by humans.
  • the foods and drinks include foods in the form of functional display foods, foods for specified health use, supplements for nutritional supplements, and the like.
  • the composition for lowering the blood CRP value, or the composition or medicament used for lowering the blood CRP value is preferably in the form of a composition taken orally or nasally, more preferably. In the form of a composition to be taken orally.
  • the composition for lowering the blood CRP value, or the composition or medicament used for lowering the blood CRP value may be taken continuously or taken as needed. There may be.
  • composition for lowering the blood CRP value or the specific form of the composition or medicament used for lowering the blood CRP value will be described later.
  • composition of the present invention is an anti-inflammatory composition, composition for lowering blood CRP level, composition or medicine used for treatment or prevention of inflammation, or used for lowering blood CRP level
  • the composition or medicine may be the active ingredient itself (turmeronol A and / or turmeronol B, or a turmeric extract containing the active ingredient).
  • it may be a composition containing the active ingredient and at least one other ingredient.
  • the composition of the present invention contains the active ingredient and at least one other component
  • the composition may be a mixture of the active ingredient and at least one other component
  • a composition in which the active ingredient and at least one other ingredient are formulated by an appropriate means may be used, or a formulation in which the active ingredient and at least one other ingredient are formulated. Further, it may be a composition mixed with other components.
  • the shape of the composition of the present invention is not particularly limited, and may be any shape such as liquid, fluid, gel, semi-solid, or solid.
  • the at least one other component that can be contained in the composition of the present invention is not particularly limited, but is preferably acceptable in a final form such as pharmaceuticals, foods and drinks, feeds, food additives, feed additives, and the like. Examples of such components that can be taken orally can be exemplified.
  • Such other components include sweeteners, acidulants, vitamins, minerals, thickeners, emulsifiers, antioxidants, and water.
  • Sweeteners include monosaccharides and disaccharides such as glucose, fructose, sucrose, lactose, maltose, palatinose, trehalose, and xylose, isomerized sugar (glucose fructose liquid sugar, fructose glucose liquid sugar, sugar mixed isomerized sugar, etc.) Sugar alcohols (erythritol, xylitol, lactitol, palatinit, sorbitol, reduced starch syrup, etc.), honey, high intensity sweeteners (sucralose, acesulfame potassium, thaumatin, stevia, aspartame, etc.).
  • sour agent examples include citric acid, malic acid, gluconic acid, tartaric acid, lactic acid, phosphoric acid, and salts thereof, and one or more of these can be used.
  • vitamins examples include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin E, niacin, inositol and the like.
  • Minerals include calcium, magnesium, zinc, iron and the like.
  • thickener examples include carrageenan, gellan gum, xanthan gum, gum arabic, tamarind gum, guar gum, locust bean gum, karaya gum, agar, gelatin, pectin, soybean polysaccharide, carboxymethylcellulose (CMC) and the like.
  • emulsifier examples include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, lecithin, vegetable sterol, and saponin.
  • antioxidants examples include vitamin C, tocopherol (vitamin E), enzyme-treated rutin, catechin and the like.
  • compositions such as foods and drinks and pharmaceuticals.
  • composition forms in which the active ingredient and at least one other ingredient are formulated by appropriate means are powders, granules, capsules, tablets (coated tablets such as sugar-coated tablets or multilayer tablets, mouth disintegrants, chewables) It may be in the form of a solid composition such as a tablet or the like, or it may be in the form of a liquid composition such as a solution.
  • the structure of isolated turomerol A is based on the results of instrumental analysis such as 1 H NMR, 13 C NMR, LCMS, and known information (Agric. Biol. Chem., 1990; 54 (9): 2367-71). Identified.
  • Termelonol B was purchased from Nagara Science Co., Ltd., dissolved in dimethyl sulfoxide, and used for the test.
  • the mouse macrophage cell line RAW264.7 was used for the experiment, seeded in a 96-well plate with DMEM (10% FBS) medium to a number of 1.5 ⁇ 10 5 cells, and CO 2 incubator for 24 hours. Incubated until confluent.
  • the mouse macrophage cell line RAW264.7 cultured in a 96-well plate was selected from predetermined concentrations (1.7 ⁇ g / mL, 3.2 ⁇ g / mL, 6.3 ⁇ g / mL, 12.5 ⁇ g / mL, and 25 ⁇ g / mL).
  • LPS lipopolysaccharide
  • control / LPS (+) is the test group in which the same operation is performed except that the cells are not treated with tureronol A or tureronol B, and the same operation as control / LPS (+) is performed except that LPS is not added to the medium during the 12-hour culture.
  • the test group where the test was performed was defined as control / LPS ( ⁇ ).
  • Test food Tablets ingested by subjects in the turmeric extract intake group were prepared using the above-mentioned turmeric extract, maltose, fine silicon dioxide, sucrose fatty acid ester, and brightener.
  • the amount of turmeronol A and turmeronol B in this tablet was measured using LC / MS according to the procedure described later.
  • the amount of curcumin in the tablet was measured using HPLC according to the procedure described later.
  • the single dose (3 tablets) of one subject of this tablet contained 86.5 ⁇ g of turmeronol A, 24.7 ⁇ g of turmeronol B, and 471 ⁇ g of curcumin.
  • Tablets taken by subjects in the placebo intake group were prepared using maltose, pigment, fine silicon dioxide, sucrose fatty acid ester, and brightener.
  • turmeric extract intake group and the placebo intake group consists of 45 subjects who satisfy the following conditions. Men and women aged 50 to 69 years BMI is normally high to obese 1 degree (BMI: 23 to less than 30), or blood pressure is normal blood pressure to I degree hypertension (systolic blood pressure: 120 mmHg to 160 mmHg, or Diastolic blood pressure: 80mmHg or more and less than 100mmHg) A certain number was selected.
  • Placebo-controlled double-blind parallel group comparison study 45 subjects in the turmeric extract intake group orally ingested 3 tablets containing the turmeric extract daily for 12 weeks before dinner.
  • the turmeric extract intake group 2 subjects during the 12-week study became dropouts or exclusion criteria subjects and 43 completed the study.
  • the blood CRP (c-reactive protein) value of each subject was measured to obtain an average value.
  • the blood CRP value was measured by the nephelometry method and the latex agglutination turbidimetry.
  • the measurement by the neferometry method was performed according to the N-latex CRP II kit of Siemens Healthcare Diagnostics.
  • the measurement by latex agglutination turbidimetry was carried out according to the Iatro CRP-EX kit of LSI Rulece.
  • the present invention is useful in the field of food and drink or pharmaceuticals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition présentant une activité anti-inflammatoire ou une action faisant baisser la valeur de la protéine C-réactive (CRP, pour "C-Reactive Protein") sanguine, la composition contenant un composé dérivé d'une substance alimentaire qui est très sûre et a une longue histoire d'utilisation comme aliment. La présente invention concerne une composition destinée à être prise par voie orale, une composition anti-inflammatoire, ou une composition permettant de faire baisser la valeur de la CRP sanguine, qui contient par ingestion une quantité totale de 100 µg ou plus de turméronol A et/ou de turméronol B . La présente invention concerne également une composition destinée à être prise par voie orale, une composition anti-inflammatoire, ou une composition permettant de faire baisser la valeur de la CRP sanguine, qui contient par ingestion 80 µg ou plus de turméronol A et/ou 20 μg ou plus de turméronol B.
PCT/JP2019/016764 2018-04-20 2019-04-19 Composition contenant du turméronol a et/ou du turméronol b WO2019203338A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-081700 2018-04-20
JP2018081700A JP2019189544A (ja) 2018-04-20 2018-04-20 ターメロノールａ及び／又はターメロノールｂを含有する組成物

Publications (1)

Publication Number Publication Date
WO2019203338A1 true WO2019203338A1 (fr) 2019-10-24

Family

ID=68239684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/016764 WO2019203338A1 (fr) 2018-04-20 2019-04-19 Composition contenant du turméronol a et/ou du turméronol b

Country Status (3)

Country Link
JP (1) JP2019189544A (fr)
TW (1) TW201943413A (fr)
WO (1) WO2019203338A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016199491A (ja) * 2015-04-09 2016-12-01 ハウスウェルネスフーズ株式会社 気分状態改善剤
JP2016216441A (ja) * 2015-05-20 2016-12-22 ゼリア新薬工業株式会社 内用液剤
JP2018008912A (ja) * 2016-07-15 2018-01-18 ハウスウェルネスフーズ株式会社 臓器線維化抑制組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266586A1 (fr) * 2004-03-23 2010-12-29 Lifeline Nutraceuticals Corporation Composition et méthode pour alléger l'inflammation et stress oxydatif dans les Mammifèrs.
JP2008280333A (ja) * 2007-04-10 2008-11-20 Yoshinari Matsui 末期癌等治療用医薬組成物
JP5511895B2 (ja) * 2012-06-07 2014-06-04 アントニイ ベニー クルクミンの生物学的利用率を向上させるための組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016199491A (ja) * 2015-04-09 2016-12-01 ハウスウェルネスフーズ株式会社 気分状態改善剤
JP2016216441A (ja) * 2015-05-20 2016-12-22 ゼリア新薬工業株式会社 内用液剤
JP2018008912A (ja) * 2016-07-15 2018-01-18 ハウスウェルネスフーズ株式会社 臓器線維化抑制組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU, J. ET AL.: "Absolute Configurations and NO Inhibitory Activities of Terpenoids from Curcuma longa", J. AGRIC. FOOD CHEM., vol. 63, no. 24, 2015, pages 5805 - 5812, XP055546595, DOI: 10.1021/acs.jafc.5b01584 *

Also Published As

Publication number Publication date
JP2019189544A (ja) 2019-10-31
TW201943413A (zh) 2019-11-16

Similar Documents

Publication Publication Date Title
US8741364B2 (en) Method of improving fat metabolism
JP4686173B2 (ja) ポリフェノールおよび／またはビタミンｃを含有するアセロラ処理物
JP6803893B2 (ja) Ｖｃａｍ−１発現抑制剤
JP6773361B2 (ja) 気分状態改善剤
JP5543651B1 (ja) ウコン中の有用成分及びウコン色素を含有する液状組成物
Halaby et al. Protective and curative effect of garden cress seeds on acute renal failure in male albino rats
KR101820096B1 (ko) 콩 발아배아 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물
WO2020004357A1 (fr) COMPOSITION POUR TRAITER, PRÉVENIR OU ATTÉNUER LA MALADIE D'ALZHEIMER, COMPOSITION POUR INHIBER LA MORT DES CELLULES NERVEUSES CRÂNIENNES, COMPOSITION POUR INHIBER L'ACTIVATION DE LA MICROGLIE INDUITE PAR LE PEPTIDE β-AMYLOÏDE, ET COMPOSITION POUR INHIBER LA PRODUCTION DE PGE2, TNF-α OU IL-1β INDUITE PAR LE PEPTIDE β-AMYLOÏDE
WO2021002334A1 (fr) COMPOSITION PERMETTANT D'INHIBER LA PRODUCTION DE TNF-α OU D'IL-6
JP2018506524A (ja) バーンアウト症候群の予防、改善、または治療用組成物
WO2019203338A1 (fr) Composition contenant du turméronol a et/ou du turméronol b
WO2019198661A1 (fr) Composition d'inhibition de la prolifération de cellules cancéreuses, composition anti-cancéreuse, composition de prévention de la cancérisation de cellules normales, composition de prévention de l'apparition de cancer, et composition d'induction de la mort de cellules cancéreuses
WO2018207910A1 (fr) Composition anti-inflammatoire
JP2012131760A (ja) 脂肪酸吸収抑制剤
JP7452776B2 (ja) 血圧降下用組成物
JP5282202B2 (ja) 抗ストレス剤または睡眠改善剤
JP6835396B2 (ja) 血中グルコース濃度低減用、血中ヘモグロビンＡ１ｃ量低減用又は血中ＨＤＬ−コレステロール量増加用組成物
JP7452777B2 (ja) 生活の質改善又は維持用組成物
TWI810644B (zh) 治療性草藥組合物
JP6806729B2 (ja) 黒大豆種皮抽出物とヒハツ抽出物を必須成分として含有する、血清中一酸化窒素産生増強用、肝臓中抗酸化機能改善促進用および血清中中性脂肪量低下機能促進用の可食性組成物および血管内皮機能改善剤
US20070269540A1 (en) Fat metabolism improving agent
JP2022072006A (ja) アドレノメデュリン遺伝子発現増強用組成物
CA2558465C (fr) Ameliorant metabolique des graisses
KR20230033211A (ko) 고깔양배추 추출물을 유효성분으로 함유하는 항염증 조성물
JP2009234919A (ja) 治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19788484

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19788484

Country of ref document: EP

Kind code of ref document: A1